Health Condition 1: O998- Other specified diseases and conditions complicating pregnancy, childbirth and the puerperium
Conditions
Interventions
Intervention1: DMPA + Atorvastatin: DMPA - 150mg (IM) once in 3 months, Atorvastatin: 20 mg once daily
Control Intervention1: Comparing DMPA + Atorvastatin in the treatment of adenomyosis with DMPA: S
Sponsors
SRM college of pharamacy
Eligibility
Inclusion criteria
Inclusion criteria: patients diagnosed with adenomyosis in ultrasonography patients willing to participate patient willing to be on contraceptives during study period
Exclusion criteria
Exclusion criteria: patients planning for pregnancy pregnant and lactating patients patients with mental illness patients who are already in any other hormonal treatment for adenomyosis patients who have undergone surgery (less than 6 months) patients diagnosed with mild hepatic dysfunction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the change in pain as measured by Wong Bakers FACES pain rating scale in patients receiving DMPA + Atorvastatin and DMPA alone To assess the change in abnormal uterine bleeding as measured by the UFS-QOL questionnaire in patients receiving DMPA + Atorvastatin and DMPA aloneTimepoint: Patients will be followed at the end of 4, 8 and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the change in uterine volume and vascularity by measuring the pulsatility index by transvaginal USG (MUSA criteria) To assess the quality of life in patients using UFS-QOL questionnaire To assess the Hb level on day 2 as measured by blood samples in patients with adenomyosis Timepoint: Patients will be followed at the end of 4, 8 and 12 weeks | — |
Countries
India
Contacts
Public ContactSK NITHYASHREE
SRM INSTITUTION
Outcome results
None listed